Product Description: Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs)[1][2][3][4].
Applications: Neuroscience-Neurodegeneration
Formula: C21H26N2S2
Citations: Int J Mol Sci. 2023, 24(2), 1635./Br J Cancer. 2024 Aug 22./Int J Biol Macromol. 25 December 2021./Pol J Microbiol. 2019 Dec;68(4):477-491.
References: [1]Tschanz JT, et, al. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1988 Nov;31(3):519-22./[2]Mu J, et, al. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014 May;31(5):2107-14./[3]Kang S, et, al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012 Sep;17(9):989-97./[4]Loehr AR, et, al. Targeting Cancer Stem Cells with Differentiation Agents as an Alternative to Genotoxic Chemotherapy for the Treatment of Malignant Testicular Germ Cell Tumors. Cancers (Basel). 2021 Apr 23;13(9):2045.
CAS Number: 50-52-2
Molecular Weight: 370.57
Research Area: Neurological Disease; Cancer
Solubility: 10 mM in DMSO
Target: 5-HT Receptor;Apoptosis;Autophagy;Bacterial;Dopamine Receptor
English
Deutsch
